Bronchitis News and Research

RSS

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

70% of COPD patients under-diagnosed due to lack of disease knowledge

"It is high time to demystify COPD in order to better explain the issues and help people who suffer from this disease," says Dr. Jean Bourbeau, Director of the Respiratory, Epidemiology and Clinical Research Unit at the Montreal Chest Institute of the MUHC, and lead investigator of CanCOLD along with Dr. Wan Tan of The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia.

17 Apr 2010

Volcanic ash falls across Europe

Flights were cancelled across Europe today thanks to volcanic ash drifting in to northern Europe from Iceland. More than 250 flights were grounded from London’s Gatwick and Heathrow airports alone, leaving thousands of passengers stranded. The ash is drifting in from a volcanic eruption in Iceland and the cloud is capable of damaging jet engines that travel through it.

16 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

Adolescent inhalant misuse can lead to deadly consequences

Approximately 143,000 young people aged 12 to 17 used inhalants in the past year while dealing with a condition like pneumonia, bronchitis, asthma, or sinusitis, according to a new study sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA). The study determined that the rate of use was 4.4 percent among adolescents who had at least one of the aforementioned respiratory conditions, similar to the rate among adolescents overall (4.1 percent).

8 Apr 2010

Pernix Therapeutics Holdings acquires oral third-generation cephalosporin, CEDAX

Pernix Therapeutics Holdings, Inc. today announced the acquisition of the antibiotic CEDAX® (ceftibuten) from Shionogi Pharma, Inc.

25 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription drugs, according to a study released today by the Canadian Institute for Health Information.

19 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

The U.S. Food and Drug Administration today approved Botox (onabotulinumtoxin A) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis.

10 Mar 2010

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Allergan, Inc. today announced that the United States Food and Drug Administration has approved BOTOX® (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity.

9 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

California's dirty air costs more than $193M in hospital-based medical care, finds RAND study

California's dirty air caused more than $193 million in hospital-based medical care from 2005 to 2007 as people sought help for problems such as asthma and pneumonia that are triggered by elevated pollution levels, according to a new RAND Corporation study.

2 Mar 2010

Approval of smoke-free legislation: Huge step forward to protect workers and public from secondhand smoke

The Kansas Legislature today delivered a historic victory for health and the public's right to breathe clean air by passing legislation to make almost all workplaces, including all restaurants and bars, smoke-free.

26 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Patients with COPD could benefit from treatment with drugs that block sestrin function

Chronic obstructive pulmonary disease (COPD) is defined by emphysema and/or chronic bronchitis. It destroys the normal architecture of the lung and inhibits the mechanical aspects of breathing, which prevents necessary gas exchange. Patients suffer from coughing fits, wheezing, and increased incidence of lung infections.

27 Jan 2010

St. Luke’s Hospital & Health Network takes major steps to reduce its carbon footprint

St. Luke’s Hospital & Health Network has taken a major step towards reducing its carbon footprint. By purchasing 10 percent of its electricity from renewable energy sources, the health system will realize an annual 2,900 ton reduction of carbon dioxide, a significant component of greenhouse gas.

22 Jan 2010

Current research suggests flu may predispose to secondary bacterial infections

Current research suggests that the flu may predispose to secondary bacterial infections, which account for a significant proportion of mortality during flu pandemics. The related report by Lee et al, "A mouse model of lethal synergism between influenza virus and Haemophilus influenzae," appears in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Elevation Pharmaceuticals closes $30M tranched Series A financing

Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today the closing of a $30 million tranched Series A financing.

21 Jan 2010

Results of two pivotal Phase III clinical trials with oral FTY720 published

Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).

21 Jan 2010

Moxifloxacin more favorable than amoxicillin/clavulanate for COPD exacerbations

Chronic obstructive pulmonary disease (COPD) affects a large number of subjects worldwide and is characterised by a progressively rising epidemiological, clinical and socio-economic impact. The objectives of treatment are to decrease the burden of the disease through relief of symptoms, improvement of exercise tolerance, and prevention and treatment of exacerbations.

21 Jan 2010

Bronchitis News and Research

Further Reading

70% of COPD patients under-diagnosed due to lack of disease knowledge

Volcanic ash falls across Europe

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Adolescent inhalant misuse can lead to deadly consequences

Pernix Therapeutics Holdings acquires oral third-generation cephalosporin, CEDAX

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

California's dirty air costs more than $193M in hospital-based medical care, finds RAND study

Approval of smoke-free legislation: Huge step forward to protect workers and public from secondhand smoke

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Patients with COPD could benefit from treatment with drugs that block sestrin function

St. Luke’s Hospital & Health Network takes major steps to reduce its carbon footprint

Current research suggests flu may predispose to secondary bacterial infections

Elevation Pharmaceuticals closes $30M tranched Series A financing

Results of two pivotal Phase III clinical trials with oral FTY720 published

Moxifloxacin more favorable than amoxicillin/clavulanate for COPD exacerbations

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News